|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:843-849, doi:10.1016/j.jacc.2007.10.044 © 2008 by the American College of Cardiology Foundation |
Pacific Rim Electrophysiology Research Institution, Inglewood, California.
Manuscript received August 22, 2007; revised manuscript received October 10, 2007, accepted October 29, 2007.
* Reprint requests and correspondence: Dr. Koonlawee Nademanee, Pacific Rim Electrophysiology Research Institution, 575 E. Hardy Street, #201, Inglewood, California 90301. (Email: wee{at}pacificrimep.com).
Objectives: The purpose of this study was to determine the long-term clinical outcomes of catheter ablation of atrial fibrillation (AF) substrate for high-risk patients with AF.
Background: The benefits of catheter ablation for high-risk AF patients with respect to mortality and stroke reductions remain unclear.
Methods: We performed AF substrate ablation guided by complex fractionated atrial electrogram (CFAE) mapping in 674 high-risk AF patients. The clinical end points were sinus rhythm (SR), death, stroke, or bleeding. Of these 674 patients, 635 were available for follow-up and made up the study cohort. The patients were relatively old (mean age 67 ± 12 years) and 129 had an ejection fraction (EF) <40%.
Results: After the mean follow-up period of 836 ± 605 days, 517 were in SR (81.4%). There were 15 deaths among the patients who stayed in SR compared with 14 deaths among those who remained in AF (5-year survival rate, 92% vs. 64%, respectively; p < 0.0001). SR was the most important independent favorable parameter for survival (hazard ratio 0.14, 95% confidence interval 0.06 to 0.36, p < 0.0001), whereas old age was unfavorable. Warfarin therapy was discontinued in 434 of the 517 patients in SR post-ablation (84%) whose annual stroke rate was only 0.4% compared with 2% in those with continuing warfarin treatment (p = 0.004).
Conclusions: CFAE-targeted ablation of AF is effective in maintaining SR in selected high-risk AF patients and might allow patients to stop warfarin therapy. SR after AF ablation is a marker of relatively low mortality and stroke risk. Our findings support conducting further randomized studies to determine whether AF ablation is associated with mortality and/or stroke reduction.
| ||||||||||||
Related Article
J. Am. Coll. Cardiol. 2008 51: A23-A24.
This article has been cited by other articles:
![]() |
D. Steven and S. Willems How to assess the efficacy of catheter ablation of atrial fibrillation? Reply Eur. Heart J., July 2, 2008; (2008) ehn301v1. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |